GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FIT Biotech Oy (OHEL:FITBIO) » Definitions » EPS (Diluted)

FIT Biotech Oy (OHEL:FITBIO) EPS (Diluted) : €-0.02 (TTM As of Jun. 2018)


View and export this data going back to 2015. Start your Free Trial

What is FIT Biotech Oy EPS (Diluted)?

FIT Biotech Oy's Earnings per Share (Diluted) for the six months ended in Jun. 2018 was €-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 was €-0.02.

FIT Biotech Oy's EPS (Basic) for the six months ended in Jun. 2018 was €-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2018 was €-0.02.

FIT Biotech Oy's EPS without NRI for the six months ended in Jun. 2018 was €-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2018 was €-0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


FIT Biotech Oy EPS (Diluted) Historical Data

The historical data trend for FIT Biotech Oy's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FIT Biotech Oy EPS (Diluted) Chart

FIT Biotech Oy Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
EPS (Diluted)
- -0.15 0.09 -0.13 -0.05

FIT Biotech Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only -0.05 -0.08 -0.03 -0.02 -

Competitive Comparison of FIT Biotech Oy's EPS (Diluted)

For the Biotechnology subindustry, FIT Biotech Oy's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FIT Biotech Oy's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FIT Biotech Oy's PE Ratio distribution charts can be found below:

* The bar in red indicates where FIT Biotech Oy's PE Ratio falls into.



FIT Biotech Oy EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

FIT Biotech Oy's Diluted EPS for the fiscal year that ended in Dec. 2017 is calculated as

Diluted EPS (A: Dec. 2017 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.301-0)/61.417
=-0.05

FIT Biotech Oy's Diluted EPS for the quarter that ended in Jun. 2018 is calculated as

Diluted EPS (Q: Jun. 2018 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.832-0)/981.413
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FIT Biotech Oy  (OHEL:FITBIO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


FIT Biotech Oy EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of FIT Biotech Oy's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


FIT Biotech Oy (OHEL:FITBIO) Business Description

Traded in Other Exchanges
N/A
Address
Biokatu 12, Tampere, FIN, FI-33520
FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.

FIT Biotech Oy (OHEL:FITBIO) Headlines

No Headlines